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Bronchial hyperresponsiveness in children with atopic rhinitis:
a 7-year follow-up
Non-speciﬁc bronchial hyperresponsiveness (BHR) is
considered both a distinctive functional characteristic of
bronchial asthma and a signiﬁcant risk factor for the future
onset of asthma itself, expecially in children (1). Asymp-
tomatic BHR has been found to occur more frequently in
atopic subjects (2) and in those with rhinitis; therefore,
patients with BHR and allergic rhinitis are supposed to be
at higher risk for subsequent development of bronchial
asthma (3, 4). Indeed, several studies have demonstrated a
strict association between atopic status, BHR, and asthma
(5, 6), but the real clinical outcome of asymptomatic BHR,
has not still been fully ascertained (7). In parallel, although
a relationship exists between BHR and spontaneous
changes in bronchomotor tone as evaluated by peak
expiratory ﬂow (PEF) monitoring in children (8), there is
still no clear demonstration of a clinical outcome of this
relationship. Moreover, despite the suggestive epidemio-
logical evidence, the possible evolution of BHR towards
asthma in atopic patients has not been convincingly
clariﬁed in clinical conditions, e.g. in a selected population
of patients withwell-ascertained BHR, and followed up for
a long enough time period (5).
The aim of the present long-term longitudinal study
was to determine the clinical role of BHR in the
development of asthma. A selected homogeneous popu-
lation of children with allergic rhinitis alone was therefore
assessed at baseline conditions and after 7 years, in order
to evaluate the time course of BHR and atopy and their
possible role in asthma development.
Material and methods
Study design
The study is a prospective evaluation with two time-point
assessments: baseline (T0) and after 7 years (T1). At both time-
points, several parameters were evaluated including: presence of
allergic rhinitis, presence and severity of asthma, skin-prick test
(and allergy score), allergen-speciﬁc IgE measurements, total
serum IgE, pulmonary function tests and methacholine (Mch)
challenge. All parents of the patients granted their availability for
follow-up visit and signed a written informed consent. The study
was approved by the inner Ethical Committee. According to the
Italian law, the respect of individual privacy concerning clinical
data was granted.
Background: A high prevalence of bronchial hyperresponsiveness (BHR) was
found in atopic subjects with rhinitis. Those subjects may be at higher risk for
developing bronchial asthma. We evaluated, in a 7-year follow-up, BHR and
atopy in a homogeneous population of nonasthmatic children with allergic
rhinitis (AR), and their role in asthma development.
Methods: Twenty-eight children (6–15 years) with AR were studied. At enroll-
ment (T0), skin tests, total serum IgE assay, peak expiratory ﬂow (PEF) mon-
itoring and methacholine (Mch) bronchial challenge were performed. BHR was
computed as the Mch dose causing a 20% forced expiratory volume (FEV)1 fall
(PD20FEV1) and as dose–response slope (DRS). Subjects were reassessed after
7 years (T1) using the same criteria.
Results: At T0, 13 children (46%), showing a PD20FEV1 <1526 lg of Mch, had
BHR (Mch+), although PEF variability (PEFv) was within normal limits. None
of the children with negative methacholine test developed bronchial asthma after
7 years. Of the 13 Mch+, only two reported asthma symptoms after 7 years. No
signiﬁcant change was seen in the other parameters of atopy considered.
Conclusion: Children with allergic rhinitis present a high prevalence of BHR.
Nevertheless, their PEFv is normal and the rate of asthma development low.
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Patients and diagnosis
Twenty-eight children (15 female, 13 male, mean age 10.4 years, age
range 6–15 years) were enrolled in the study (T0). The subjects were
selected from outpatients consecutively referred to the Allergy Unit
of the Department of Pediatrics, Palermo University, according to
the following strict criteria. All children had to suﬀer from allergic
rhinitis (9), assessed by a clinical history of nasal blockage, sneezing,
itching and discharge (not caused by common cold), in the last
2 years. The allergic mechanism had to be conﬁrmed through skin-
prick test and allergen-speciﬁc IgE measurements. None of the
subjects had a personal history of diurnal/nocturnal dry cough,
isolated or recurrent diurnal/nocturnal episodes of wheezing,
recurrent episodes of diﬃcult breathing and/or chest tightness at
rest or with physical activity (10). Skin tests were performed with a
standard panel of commercial allergen extracts (Lofarma S.p.A,
Milan, Italy) including: Dermatophagoides pteronyssinus, grasses,
Parietaria judaica, Phleum pratense, Artemisia, olive, dog and cat
dander, Alternaria, and Cladosporium, plus a positive (histamine
1%) and a negative (saline) control. Following the EAACI recom-
mendations, the positivity was measured after 15 min as the mean
of the major diameter of the wheal plus its orthogonal. Reactions of
5 mm or greater were considered positive (11). The allergy score was
deﬁned as the number of positive skin reactions. Total serum IgE
were determined by latex nephelometry (Behring Institute,
L’Aquila, Italy), log transformed and expressed as Z-scores (12),
according to the age groups 6–10 and 11–15 years. Allergen-speciﬁc
IgE were measured by FEIA-CAP System (Pharmacia, Upssala,
Sweden). The cut-oﬀ limit for speciﬁc IgE was 0.35 kU/l: levels
above this limit were considered positive (CAP class I). The age of
onset and duration of rhinitis, passive and active smoking were
assessed. Familial atopic risk was classiﬁed according to the criteria
of Croner and Kjellman (13). At T0, rhinitis was re-deﬁned as
persistent (symptoms at least 4 days/week and >4 weeks/year) or
intermittent (symptoms <4 days/week or <4 weeks/year),
according to the ARIA guidelines (14). As expected, the subjects
with persistent rhinitis were those with positive skin tests for Dermat-
ophagoides and/or Parietaria: in fact, in the southern Mediterranean
area, Parietaria has a very long period of pollination. At T1, all
subjects were again interviewed to ascertain whether (i) asthma
symptoms had developed during the preceding 7 years; (ii) diagnosis
of bronchial asthma had been made by a physician; (iii) clinical
symptoms of bronchial asthma were actually present. Skin-prick
test and Mch challenge were repeated, and any pharmacological
treatment (nasal steroids, or speciﬁc immunotherapy) was also
recorded. All children were free of upper or lower respiratory
infections in the 30 days preceding the clinical evaluations (15).
Pulmonary function tests and Mch challenge
Pulmonary function tests (PFT) were performed in all subjects at T0
and T1 by a computerized water-sealed spirometer (Biomedin, Pa-
dua, Italy). Methacholine bronchial provocation tests were per-
formed at T0 and T1 at the same hour of the day and under the same
environmental conditions. Subjects with positive skin tests for sea-
sonal pollens were challenged outside the pollen season. Moreover,
to minimize exposure to Parietaria pollen, subjects were tested in
the period December–February at both T0 and T1. An ampoule-
dosimeter (Mefar Elettromedicali, Bovezzo, Brescia, Italy) was
used. An inspiratory eﬀort activated a solenoid valve for 0.5 s
delivering 5 ll of solution. After using a saline solution as control,
Mch was administered in doubling increasing amounts beginning
with a starting dose of 50 lg. The forced vital capacity (FVC) and
the forced expiratory volume (FEV) in the ﬁrst second (FEV1) were
recorded approximately 2 min after each inhalation (15). The
cumulative administered dose of Mch causing a reduction of 20% of
the baseline FEV1 (PD20) was calculated by interpolating the
cumulative doses immediately preceding and following the 20%
FEV1 fall. Subjects showing a PD20 <7.8 lmol Mch, equivalent to
1526 lg (16), were considered as responders (Mch+). We deﬁned
persistent Mch) subjects nonresponders at both T0 and T1; tran-
sient Mch) nonresponders at T0 and responders at T1; transient
Mch+ responders at T0 and nonresponders at T1; and persistent
Mch+, the responders at both T0 and T1.
Dose–response slopes (DRS) were calculated for each subject as
the ratio between percent decline in FEV1 (from the postsaline va-
lue) over the cumulative dose of Mch (17). Using this procedure, a
continuous index of BHR was also obtained in the nonresponders
(Mch)) in which a FEV1 fall >20% was not obtained.
At T0, the subjects were instructed to use twice daily (after awa-
kening and at bedtime) a portable peak expiratory ﬂow rate meter
(Mini Wright Peak Flow Meter, Clement Clarke Ltd, London,
UK), selecting the best of three consecutive measurements. PEF
measurements and any respiratory symptom occurring over a
14-consecutive day period were recorded on a diary card. PEF
variability (PEFv) was computed as the mean on 14 days of the
daily diﬀerences between the highest and lowest values expressed as
the percent of the daily mean.
Changes in DRS from T0 to T1 were considered signiﬁcant if the
absolute value of the diﬀerence of DRS values between T1 and T0
(DDRS) was ‡2 SD of DRS at T0.
Statistical analysis
As the distribution of DRS values was highly skewed, results of all
analyses were expressed as values after natural log transformation
(ln DRS) (18). The diﬀerences between the two groups were analysed
using the anova and chi-squared analysis. For paired comparison,
Student’s t-test for paired data and Wilcoxon signed rank test were
used. The relationships between diﬀerent variables were tested by
simple and multiple linear regression analysis. A P-value <0.05 was
considered signiﬁcant.
Results
At baseline, 13 of 28 patients (46%) were MCh+. The
clinical characteristics of our sample are summarized in
Table 1. Baseline FVC and FEV1 were >80% of the
predicted value in all subjects (Table 2). Predicted values
were those from Polgar for subjects <18 years of age and
ECCS for subjects ‡18 years. In the overall sample, the
number of positive skin-prick tests was in the range 1–6 at
T0 and in the range 1–7 at T1 (Table 2). Disease duration
was not signiﬁcantly diﬀerent between Mch+ and Mch)
Table 1. Clinical characteristics of the sample at baseline time-point (T0)
Mch+ Mch)
No. patients (n ¼ 28) 13 15
Mean age (years; €SD) 9.2 € 1.8 11.5 € 1.9
Mean height (cm; €SD) 139 € 10 144 € 12
Sex (M/F) 8/5 5/10
Persistent/intermittent rhinitis (n) 12/1 12/3
Atopic rhinitis: a 7-year follow-up
1075
subjects at both T0 and T1 (Table 2). None of the subject
was a smoker at T0; only ﬁve were active smokers at T1,
but none of them had a smoke history of >1 pack-year.
The exposure to passive smoke was not signiﬁcantly
associated with Mch response at T0. Conversely, at T1,
Mch+ subjects were 10 of 13 among those exposed to
passive smoke, and only four of 15 among those not
exposed (P ¼ 0.008, chi-squared test; Table 2). The
frequency distribution of the course of rhinitis did not
diﬀer between Mch+ and Mch) subjects at both T0 and
T1 (chi-squared test; Table 3). Baseline FVC, FEV1 (% of
predicted) and FEV1/FVC ratio were not signiﬁcantly
diﬀerent between Mch+ and Mch) subjects at both T0
and T1 (anova; Table 2). Moreover, the individual FEV1/
FVC ratio did not signiﬁcantly change between T0 and T1
(t-test for paired data; P ¼ 0.11).
At T0, the 13 Mch+ subjects had a median PD20 of
660 lg; their median DRS was 0.038%FEV1/lgMch
(Table 2). At T1, 14 of 28 subjects were Mch+, with a
median PD20 of 431 lg and a median DRS of 0.036, as
summarized in Table 2. No signiﬁcant diﬀerence was
found in overall DRS between T0 and T1 (Wilcoxon
signed rank test). The frequency distribution of Mch+
and Mch) subjects was not signiﬁcantly diﬀerent between
T0 and T1 (chi-squared), nevertheless, only eight Mch+
subjects were persistent Mch+ and nine Mch) were
persistent Mch). Moreover, six subjects were transient
Mch) and ﬁve transient Mch+ after 7 years (Fig. 1). The
subgroup of persistent Mch+ was signiﬁcanly associated
with passive smoke exposure (P ¼ 0.03; chi-squared test).
Only four subjects showed changes in DRS >2 SD; BHR
was increased in three subjects and decreased in one. All
the four subjects were persistent Mch+.
Only ﬁve subjects followed a regular therapeutic
regimen with nasal steroids and ﬁve subjects underwent
speciﬁc immunotherapy during the 7 years preceding the
follow-up visit. None of the therapeutic regimens (regular
nasal steroids or speciﬁc immunotherapy) was associated
to any class of change in Mch response. In particular,
among subjects who underwent speciﬁc immunotherapy,
two were persistent Mch+, two transient Mch), and one
transient Mch+; among subjects who used regular nasal
steroids, two were transient Mch), two transient Mch+,
and one persistent Mch). At T0, ln DRS showed a
signiﬁcant inverse linear relationship with age
(R2 ¼ 0.147, P ¼ 0.044; Fig. 2). At T1, ln DRS showed
a signiﬁcant inverse linear relationship with disease
duration (R2 ¼ 0.146, P ¼ 0.044; Fig. 3). The linear
regression analysis between disease duration and age
was not signiﬁcant at T1 (P ¼ 0.60). A signiﬁcant positive
linear relationship was found between ln DRS at T1 and
ln DRS at T0 (R
2 ¼ 0.303, P ¼ 0.0024; Fig. 1).
Table 2. Clinical and pulmonary function test characteristics of the studied population at enrollment (T0) and at follow-up visit (T1)
T0 T1 P-value
Mch+ (n ¼ 13) Mch) (n ¼ 15) Mch+ (n ¼ 14) Mch) (n ¼ 14) N.S. (chi-squared test)
Age (years)* 9.2 € 1.8 11.5 € 1.9 16.6 € 2.6 17.0 € 2.2 N.S. (anova)
Disease duration (years)* 4.6 € 3.1 3.6 € 2.7 9.1 € 1.9 11.8 € 3.3 N.S. (anova)
Familial atopic risk* 1.2 € 1.2 0.7 € 0.9 N.S. (anova)
Passive smoke (Y/N) 8/5 5/10 10/4 3/11 P ¼ 0.008 at T1
(chi-squared test)
Allergy score 2.7 (1–6) 2.3 (1–6) 2.0 (1–7) 2.0 (1–3) N.S. (anova)
IgE Z-score* 0.28 € 0.97 )0.11 € 1.11 N.S. (anova)
FVC (% pred)* 110 € 9 113 € 11 111 € 16 112 € 16 N.S. (anova)
FEV1 (L)* 2.2 € 0.3 2.7 € 0.7 3.5 € 0.6 3.8 € 0.8 N.S. (anova)
FEV1 (% pred)* 109 € 113 113 € 11 111 € 16 117 € 15 N.S. (anova)
FEV1/FVC (%)* 91 € 7 93 € 6 88 € 6 91 € 5 N.S. (anova)
PEFv (%)* 5.4 € 2.4 5.2 € 2.4 N.S. (anova)
PDz20 (lg Mch) 660 (195–1415) 431 (82–1225) N.S. (WSRT)
DzRS (%FEV1/lg Mch) 0.038 (0.016–0.102) 0.003 (0.0006–0.0127) 0.036 (0.017–0.211) 0.0038 (0.0002–0.0118) N.S. (WSRT)
PD20, cumulative administered dose of methacholine causing a reduction of 20% of the baseline FEV1. Those subjects with PD20 £ 1526 lg were considered Mch+
(responders).
DRS, methacholine dose–response slope.
Data are shown as mean € SD*, as mean and range, and as median and range.
N.S., P-value not significant; anova, one-way analysis of variance; WSRT, Wilcoxon signed rank test.
Table 3. Contingency tables relevant to distribution of subjects with different rhi-
nitis course in responder (Mch+) and non responder (Mch)) groups, at enrollment
(T0) and at follow-up visit (T1)
Persistent Intermittent Total
T0
Mch+ 12 1 13
Mch) 12 3 15
T1
Mch+ 9 5 14
Mch) 9 5 14
Differences in frequency distribution were not statistically significant at both T0 and
T1 (chi-squared test).
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Age, IgE Z-score, allergy score, familial atopic risk, age
of disease onset, active or passive smoke exposure and
duration of disease were not signiﬁcantly diﬀerent within
groups. At T0, the presence of mite skin positivity was
signiﬁcantly associated with the Mch+ subgroup
(chi-squared test; P ¼ 0.017), whereas the association
disappeared at T1.
No signiﬁcant diﬀerence was found in PEFv between
Mch+ and Mch) subgroups at T0 (Table 2). Only one
subject persistent Mch+ showed a high PEFv (11.6%).
The ln DRS at T1 was signiﬁcantly related to PEF
variability at T0 (P ¼ 0.008, R2 ¼ 0.239). Multiple linear
regression between BHR level at T0, PEF variability, IgE
Z-score, presence/absence of indoor allergens (Dermat-
ophagoides), and exposure to passive smoke as independ-
ent variables and BHR at T1 as dependent variable
produced a large increase in R2 (0.492).
At T1, only three subjects reported development of
mild intermittent asthma (10) during the 7-year follow-
up: all three subjects were Mch+ at T0, but only two were
persistent Mch+. Consequently, we assumed that only
two of 28 subjects developed bronchial asthma during the
7-year interval. These two subjects showed PD20 at T0 of
240 and 388 lg of Mch, and PEFv of 7.7 and 3.9%
respectively. Their PD20 values at T1 were 82 and 220 lg
of Mch, respectively. Both were positive to mites, had a
familial atopic risk of 1 and an allergy score of 2 and 3,
respectively. Only one reported asthma symptoms in the
last year, showing an FEV1 <80% of the predicted value
(78%) at T1.
Discussion
Our study on a small homogeneous population reﬂects
the high prevalence of BHR among children with
allergic rhinitis described previously in larger studies.
BHR was completely asymptomatic, as no spontaneous
variability of airway patency, evaluated by daily PEF
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Figure 1. Relationship between individual values of methacho-
line dose–response slope (%FEV1/lg Mch, DRS) obtained at the
follow-up visit (T1) vs DRS at the enrollment (T0). Axis are
traced in a log–log scale. For each subject, the change in
bronchial responsiveness between T0 and T1 is shown. Hori-
zontal and vertical dashed lines depict the DRS value corres-
ponding to MchPD20 of 1526 lg of methacholine. The identity
line is plotted. Persistent Mch): nonresponders at both T0 and
T1; transient Mch): nonresponder at T0 and responder at T1;
transient Mch+: responder at T0 and nonresponder at T1;
persistent Mch+: responder at both T0 and T1.
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Figure 2. Relationship between the natural log of methacholine
dose–response slope (%FEV1/lg Mch, ln DRS) and age (years),
at enrollment (T0). The linear regression was signiﬁcant
(P ¼ 0.044, R2 ¼ 0.147).
0.2
0.16
0.12
0.08
0.04
0
In
D
R
S
7 8 9 10
Disease duration
11 12 13 14 15 16 17 18
Figure 3. Relationship between the natural log of methacholine
dose-response slope (%FEV1/Mch, ln DRS) and disease dur-
ation (years), at the follow-up visit (T1). The linear regression
was signiﬁcant (P ¼ 0.044, R2 ¼ 0.146).
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variability, could be detected. Our 7-year follow-up
showed that two of the 13 Mch+ subjects at T1 (15%)
developed mild intermittent asthma, whereas the overall
BHR degree and atopic status did not change. At T1,
BHR was related to baseline BHR and to PEF
variability. Moreover, also IgE Z-score, sensitization to
mites, and exposure to passive smoke appeared to
maintain BHR.
A high prevalence (37%) of BHR was found in a
previous study by Koh et al. (19), in a sample of
nonasthmatic children with allergic rhinitis. Rasmussen
et al. (20) showed that among children with asympto-
matic BHR at the age of 9 years, 13% had developed
asthma at age of 15 years. Similar results were obtained
in adults by Laprise and Boulet (6), who suggested that
asymptomatic BHR may represent an intermediate
stage between normal and asthmatic subjects, although
it is not clear how many patients skew from normality
to illness and why. Moreover, in this above-mentioned
study, allergen exposure appeared to be one of the
main risk factors for asthma development. In
agreement, we found that the two subjects who
developed asthma symptoms were sensitized to indoor
allergens.
In our study, none of the Mch) subjects at T0
developed asthma during the subsequent 7-year follow-
up. This conﬁrms the good predictive value of a negative
Mch bronchial challenge. Among the 13 Mch+ at T0, we
found a low rate of asthma development: only three
subjects reported intermittent asthma symptoms in the
subsequent follow-up, but one of them had become Mch)
at T1. Therefore, during the 7-year follow-up, we assumed
an asthma development rate of 15% (two among 13
subjects Mch+ at T0). One of the two subjects reporting
asthma showed asthmatic symptoms in the last year
before T1 and had a FEV1 of <80% of the predicted
value. Our results are in agreement with those of Prieto et
al. (21) who showed that asymptomatic adult subjects
with allergic rhinitis and Mch positivity did not show an
increased susceptility to asthma onset over a follow-up
period of 3.5 years.
The scarce relationship between BHR and asthma
development seems to be conﬁrmed by the high rate of
individual changes in airway reactivity. In fact, although
no signiﬁcant diﬀerence was found in the number of
Mch+ subjects between T0 and T1, 11 children (39% of
the total) changed their class of responsiveness, moving
from Mch+ to Mch), or vice-versa (Fig. 1). These
results conﬁrm that nonspeciﬁc BHR is only one of the
mechanisms underlying airﬂow obstruction in asthma
and its relationship with the clinical expression of asthma
is still uncertain or weak.
In our sample, all but one patient showed a PEFv
value lower than 9.26%, the value previously found as
the upper (95th percentile) limit for asymptomatic
nonasthmatic children (22). Because PEF variability
describes the spontaneous daily changes in airway
patency (23), the ﬁnding of a low rate of asthma
development is not surprising in our subgroup with
BHR. This seems to suggest that a low PEFv has a
greater clinical signiﬁcance than a positive response to
Mch challenge test.
Interestingly, we found a signiﬁcant inverse linear
correlation between DRS and age at T0 (Fig. 2): this result
suggests that, in childhood, airway geometric factors play
a fundamental role in non speciﬁc BHR, as previously
demonstrated in normal subjects (24). Thus, a potential
confounding eﬀect on changes in BHR may be played by
changes in airway caliber, that are expected during
growth. However, despite this assumption, in the present
work, in the overall sample, no signiﬁcant change in
FEV1/FVC ratio, an index of airway caliber (24), was
found between T0 and T1.
Moreover, an inverse linear relationship was found
between DRS and disease duration at T1 (Fig. 3).
Because disease duration and age were not correlated
at T1, we suppose that disease duration has an
independent eﬀect on BHR. Similarly, in young adults,
the duration of disease may aﬀect the mechanisms
underlying BHR as suggested by previous results
obtained in young asthmatics, in which the maximum
long-term response to bronchodilator treatment was
signiﬁcantly lower than in subjects having asthma for a
long time (25). This suggests that, in asthmatics, the
progression of disease reduces the changes in airway
motor tone, possibly because of airway remodeling. In
subjects with allergic rhinitis and asymptomatic BHR, it
remains to be established if that relationship recognizes
similar underlying mechanisms.
We found that all the subjects showed positive SPT at
T1 without any signiﬁcant change in allergy score over
time. The exposure to mites was associated with positive
BHR response at T0. Exposure to indoor allergens and to
passive smoke, BHR degree, and PEFv at T0 were the
only factors signiﬁcantly related to keeping of BHR at T1:
this was demonstrated by the R2 increase in the multiple
linear regression between BHR at T1 as a dependent
variable, and BHR at T0, PEFv, IgE Z-score, presence/
absence of indoor allergens, and exposure to passive
smoke as independent ones. However, in our sample,
such relationship did not show any clinical relevance in
terms of asthma development. In fact, the asthma
development rate we found (15%) was clearly lower than
previously reported among children with asymptomatic
BHR (26, 27).
In conclusion, this study suggests that in a 7-year
follow-up, children aﬀected by allergic rhinitis maintain a
high prevalence of bronchial hyperresponsiveness. Nev-
ertheless, the rate of asthma development remains low
and associated to a spontaneous daily variability of PEF
within normal limits and to no signiﬁcant change in their
atopic status. It remains to be ascertained if a 7-year
interval is long enough for the development of clinical
evidences of asthma symptoms.
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